Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells
Authors:
- Ming-Bo ZhaoMZMing-Bo Zhao
- Gui-Bao ZhuangGZGui-Bao Zhuang
- Ping-Ping LiPLPing-Ping Li
- 1 January 2012
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 75 (1) , 30-37
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance StatusJournal of Thoracic Oncology, 2010
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutationsJournal of Clinical Oncology, 2008
- Epidermal Growth Factor Receptor Targeting in CancerSeminars in Oncology, 2006
- Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt PhosphorylationClinical Cancer Research, 2006
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyThe Journal of Pharmacology and Experimental Therapeutics, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Epidermal growth factor receptor: a promising target in solid tumoursCancer Treatment Reviews, 2004
- Receptor Tyrosine Kinases: The Main Targets for New Anticancer TherapyCurrent Drug Targets, 2003